Table 4.
MicroRNAs selected most frequently in classifiers compared with expected frequency*
| MiR | No. of times assessed, npl (%)† | No. of times selected in classifier, ncl (%)‡ | P§ | Cancer type |
| All miRs in patients with poor outcome | ||||
| let-7 | 244 (2.46) | 16 (6.23) | <.001 | Gastric, HCC, leukemia, lung, melanoma, NHL, ovarian |
| 21 | 34 (0.34) | 5 (1.95) | .0018 | Astrocytoma, colon, lung, ovarian |
| 100 | 26 (0.26) | 4 (1.56) | .0043 | Gastric, HCC, lung |
| 125 | 71 (0.72) | 6 (2.33) | .0084 | HCC, gastric, neuroblastoma |
| MiRs with increased expression in patients with poor outcome | ||||
| 21 | 34 (0.34) | 5 (4.72) | <.001 | Astrocytoma, colon, lung, ovarian |
| 20 | 47 (0.47) | 4 (3.77) | .0046 | Colon, leukemia, NHL |
| 155 | 26 (0.26) | 3 (2.83) | .0063 | Lung, melanoma |
| 193 | 55 (0.56) | 4 (3.77) | .0078 | Melanoma |
| MiRs with decreased expression in patients with poor outcome | ||||
| let-7 | 244 (2.46) | 7 (9.59) | .0017 | Gastric, lung, HCC, ovarian |
| 30 | 135 (1.36) | 5 (6.85) | .0028 | Astrocytoma, HCC, lung |
| 29 | 94 (0.95) | 4 (5.48) | .0046 | Endometrial, NHL |
| 7039‖ | 1 (0.01) | 1 (1.37) | .0073 | Ovarian |
*
For studies assessing overall survival as an outcome with platform data available (n = 27). HCC = hepatocellular carcinoma; miR = microRNA; NHL = non-Hodgkin lymphoma.
†
From 9900 total miRs across 27 platforms.
‡
Percentages calculated for 257, 146, and 73 of the selected miRs in the all, increased expression, and decreased expression sets, respectively (for 38 selected miRs, it was not specified whether their expression was increased or decreased in patients with cancer).
§
Two-sided, using the binomial distribution to assess a statistically significant difference between npl and ncl.
‖
This is a proprietary miR from Ambion (Foster City, CA) used by Nam et al. (38).